Anticholinergic therapy for lower urinary tract symptoms associated with benign prostatic hyperplasia

Pharmacotherapy

Volumn 28, Issue 3, 2008, Pages 356-365

  Gallegos, Patrick J ^a,b,c   Frazee, Lawrence A ^a,c  

^a AKRON GENERAL MEDICAL CENTER   (United States)

^b NORTHEAST OHIO MEDICAL UNIVERSITY   (United States)

^c Northeastern Ohio Medical University   (United States)

Author keywords

Anticholinergics; Benign prostatic hyperplasia; Bladder outlet obstruction; BPH; Drug therapy; Lower urinary tract symptoms; LUTS; Tolterodine

Indexed keywords

5 ALPHA REDUCTASE INHIBITOR; ALFUZOSIN; ALPHA1 ANTAGONIST; CHOLINERGIC RECEPTOR BLOCKING AGENT; DOXAZOSIN; DUTASTERIDE; FINASTERIDE; FLAVOXATE; NAFTOPIDIL; OXYBUTYNIN; PLACEBO; PRAZOSIN; PROPIVERINE; SABAL EXTRACT; TAMSULOSIN; TERAZOSIN; TOLTERODINE; UNCLASSIFIED DRUG; URINARY TRACT AGENT;

ACUTE DISEASE; BLADDER NECK STENOSIS; CANCER RISK; CLINICAL FEATURE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DIZZINESS; DROWSINESS; DRUG EFFICACY; DRUG MECHANISM; DRUG RELEASE; DRUG SAFETY; DRUG WITHDRAWAL; FOLLOW UP; HEADACHE; HUMAN; LIFESTYLE MODIFICATION; LOW DRUG DOSE; LOWER URINARY TRACT SYMPTOM; MEN'S HEALTH; META ANALYSIS; MICTURITION; MONOTHERAPY; ORTHOSTATIC HYPOTENSION; OUTCOME ASSESSMENT; OVERACTIVE BLADDER; PATHOGENESIS; PHYTOTHERAPY; PROSTATE HYPERTROPHY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RETROGRADE EJACULATION; REVIEW; SABAL; SCORING SYSTEM; SYSTEMATIC REVIEW; TREATMENT CONTRAINDICATION; TREATMENT FAILURE; UNSPECIFIED SIDE EFFECT; URINE FLOW RATE; URINE RETENTION; URODYNAMICS; XEROSTOMIA;

CHOLESTENONE 5 ALPHA-REDUCTASE; CHOLINERGIC ANTAGONISTS; CLINICAL TRIALS AS TOPIC; HUMANS; MALE; PROSTATIC HYPERPLASIA; QUALITY OF LIFE; RECEPTORS, ADRENERGIC, ALPHA-1; URINATION DISORDERS;

EID: 40149102386     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.28.3.356     Document Type: Review

References (42)